Last reviewed · How we verify
anti-Abeta
At a glance
| Generic name | anti-Abeta |
|---|---|
| Sponsor | Genentech, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Neoadjuvant Sacituzumab Govitecan Plus Tagitanlimab for Resectable Head and Neck Squamous Cell Carcinoma (PHASE2)
- Georgia Memory Net Anti-Amyloid Monoclonal Antibody Registry
- Alzheimer's Tau Platform: Master Protocol (PHASE2)
- Alzheimer's Tau Platform: Regimen A - AADvac1 (PHASE2)
- Phase I Clinical Study of AV-1959R: Abeta-targeting Anti-Alzheimer's Vaccine (PHASE1)
- A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study) (PHASE1, PHASE2)
- Tau PET Outcomes With Anti-amyloid Immunotherapies (PHASE2)
- A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- anti-Abeta CI brief — competitive landscape report
- anti-Abeta updates RSS · CI watch RSS
- Genentech, Inc. portfolio CI